BioNexus Gene Lab Corporation (NASDAQ:BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics.
Background:
| | ● | MRNA Scientific Sdn Bhd: |
| | ○ | A wholly-owned subsidiary of BGLC, MRNA Scientific specializes in blood-based genomic screening and dynamic genome profiling.  MRNA's innovative techniques enable early disease detection, personalized health management, and AI-driven insights.
|
| | ● | Ascension Innovation Sdn Bhd (AISB): |
| | ○ | AISB is a trailblazer in healthcare technology, committed to enhancing patient experiences and outcomes. |
| | ○ | Their flagship platform, aiCMS, empowers clinics, physicians, and patients to have better control over healthcare delivery through personalized patient health management. |
Strategic Investment and Handover Ceremony:
| | · | MRNA Scientific's investment of RM 1.2 million (approx. USD $250k) will occur in two tranches. The Company has made an initial payment of approx. RM 100k, to be followed by a final payment of RM 1.1million, subject to a formal agreement. Our investment in AISB signifies a strategic move to accelerate healthcare innovation. The investment, funded internally, is expected to constitute an indicative equity of approximately 10% of the ordinary shares in AISB upon completion. |
| | · | The infusion of capital will further AISB's development and accelerate its AI rollout, including: |
| | o | AI Assistance in the Clinic and on-App: The AI features include the integration of predictive and generative AI note taking/analysis and diagnosis aids via Large Language Model (LLM), voice transcription, and natural language assistance for service selection and bookings. |
| | o | Predictive Analytics and Personalized Solutions: aiCMS will enhance early disease detection and personalized health recommendations in clinic and on-app, with the integration of in-app predictive health and wellness recommendations, medical translation services, and AI medical image analysis. |
Ceremony Participants:
| | · | MRNA Scientific Directors: |
| | | o | Mr. Kenny Lai |
| | | o | Mr. CC Wong |
| | | o | Mr. Andrew Teng (Chief Executive Officer, CEO) |
| | | o | Mrs. Penny Attenbrough (Chief Strategy Officer, CSO) |
Expanding Market Reach:
| | · | MRNA Scientific and BGLC believe that this strategic investment will allow BGLC's Blood-based Genomic Screening (BGS) liquid biopsies and other diagnostic services to be better marketed and accessible to a wider range of customers and healthcare providers, through integration into AISB's aiCMS and the aiCARE app, enabling direct booking via healthcare providers and patients. |
| | · | By combining MRNA's expertise in genomics and AISB's innovative platform, patients and healthcare professionals will benefit from advanced diagnostics and personalized care. |
Digital Health & AI Market:
| | · | The global digital health market size was estimated at USD 240.9 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 21.9% from 2024 to 20301. |
| | · | The global market size for AI in Healthcare is expected to reach USD 187.7 billion by 2030 with a compound annual growth rate (CAGR) of 38.5% from 2024 to 20302. |
| | · | Given the market size and opportunities in Digital Health and AI in Healthcare, MRNA and BGLC will closely consider opportunities to increase our participation in this market, including the potential to increase our investment in AISB and other technology platforms. |
AISB's Projections:
| | · | Projected Revenue in Malaysia: |
| | | o | As stated in its investment documents, AISB anticipates substantial revenue growth driven by increased adoption of aiCMS, with projections reaching RM 75million collectively for 2024-2028. |
| | | o | The platform's comprehensive suite of services positions it as a game-changer in the Malaysian healthcare landscape. |
| | | o | These revenue projections were part of the approved prospectus on the Securities Commission of Malaysia approved pitchIN Funding platform. |
| | · | Clinics and Service Providers: |
| | | o | AISB aims to onboard a significant number of healthcare and wellness providers, and corporations. |
| | | o | Since its recent launch, aiCMS has already proven market traction with over 30 healthcare providers and corporations in its initial segue into this broad market. |
| | · | User Base and Health Records: |
| | | o | With 145,000+ registered users and 340,000+ individual health records in its database, the aiCMS platform is already making an impact in the market. |
| | | o | The platform's scalability has the potential for exponential growth. |
Quotes:
| | · | Mr. Sam Tan, CEO, BioNexus Gene Lab Corporation: "Our investment in AISB reflects our belief in their transformative healthcare solutions. Together, we aim to revolutionize patient care through predictive and generative AI." |
| | | |
| | · | Mr. Andrew Teng, CEO, Ascension Innovation Sdn Bhd: "We welcome MRNA Scientific's support and look forward to leveraging their expertise. The future of healthcare lies in predictive analytics and personalized solutions." |
The handover ceremony took place at the Apollo Men's Wellness Centre in Starhill, Kuala Lumpur on April 18th, 2024, witnessed by Mr. Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp (BGLC).
BioNexus Gene Lab Corporation (NASDAQ:BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics.
基因组诊断和医疗保健技术的全球领导者Bionexus基因实验室公司（纳斯达克股票代码：BGLC）宣布其全资子公司MRNA Scientific Sdn Bhd对马来西亚私营公司Ascension Innovation Sdn Bhd（AISB）进行战略投资。这项投资凸显了BGLC致力于通过尖端的人工智能和预测分析来推进医疗保健解决方案的承诺。
| | ● |
MRNA Scientific Sdn Bhd: |
| | ● | MRNA Scientific Sdn Bhd： |
| | ○ | A wholly-owned subsidiary of BGLC, MRNA Scientific specializes in blood-based genomic screening and dynamic genome profiling. MRNA's innovative techniques enable early disease detection, personalized health management, and AI-driven insights. |
| | ○ | 作为BGLC的全资子公司，MRNA Scientific专门从事基于血液的基因组筛查和动态基因组分析。 MRNA 的创新技术可以实现早期疾病检测、个性化健康管理和人工智能驱动的见解。 |
| | ● |
Ascension Innovation Sdn Bhd (AISB): |
| | ● | Ascension Innovation Sdn Bhd (AISB)： |
| | ○ | AISB is a trailblazer in healthcare technology, committed to enhancing patient experiences and outcomes. |
| | ○ | Their flagship platform, aiCMS, empowers clinics, physicians, and patients to have better control over healthcare delivery through personalized patient health management. |
| | ○ | AISB是医疗保健技术的开拓者，致力于改善患者体验和疗效。 |
| | ○ | 他们的旗舰平台AICMS使诊所、医生和患者能够通过个性化的患者健康管理更好地控制医疗服务的提供。 |
Strategic Investment and Handover Ceremony:
| | · | MRNA Scientific's investment of RM 1.2 million (approx. USD $250k) will occur in two tranches. The Company has made an initial payment of approx. RM 100k, to be followed by a final payment of RM 1.1million, subject to a formal agreement. Our investment in AISB signifies a strategic move to accelerate healthcare innovation. The investment, funded internally, is expected to constitute an indicative equity of approximately 10% of the ordinary shares in AISB upon completion. |
| | · | The infusion of capital will further AISB's development and accelerate its AI rollout, including: |
| | · | MRNA Scientific的120万令吉（约合25万美元）的投资将分两批进行。根据正式协议，该公司已支付约10万令吉的首期付款，随后是110万令吉的最后一笔款项。我们对AISB的投资标志着加速医疗创新的战略举措。这项由内部融资的投资预计将在完成后构成约10％的AISB普通股的指示性股权。 |
| | · | 注入资金将进一步推动AISB的发展并加速其人工智能的推出，包括： |
| | o |
AI Assistance in the Clinic and on-App: The AI features include the integration of predictive and generative AI note taking/analysis and diagnosis aids via Large Language Model (LLM), voice transcription, and natural language assistance for service selection and bookings. |
| | o |
Predictive Analytics and Personalized Solutions: aiCMS will enhance early disease detection and personalized health recommendations in clinic and on-app, with the integration of in-app predictive health and wellness recommendations, medical translation services, and AI medical image analysis. |
| | o | 诊所和应用程序内的人工智能协助：人工智能功能包括通过大型语言模型 (LLM) 整合预测性和生成式 AI 笔记/分析和诊断辅助工具、语音转录以及用于服务选择和预订的自然语言帮助。 |
| | o | 预测分析和个性化解决方案：AICMS将整合应用内预测性健康和保健建议、医学翻译服务以及人工智能医学图像分析，从而增强临床和应用程序中的早期疾病检测和个性化健康建议。 |
| | · |
MRNA Scientific Directors: |
| | | o | Mr. Kenny Lai |
| | | o | Mr. CC Wong |
| | | o | Mr. Andrew Teng (Chief Executive Officer, CEO) |
| | | o | Mrs. Penny Attenbrough (Chief Strategy Officer, CSO) |
| | | o | 安德鲁·滕先生（首席执行官、首席执行官） |
| | | o | Penny Attenbrough 夫人（首席战略官，CSO） |
| | · | MRNA Scientific and BGLC believe that this strategic investment will allow BGLC's Blood-based Genomic Screening (BGS) liquid biopsies and other diagnostic services to be better marketed and accessible to a wider range of customers and healthcare providers, through integration into AISB's aiCMS and the aiCARE app, enabling direct booking via healthcare providers and patients. |
| | · | By combining MRNA's expertise in genomics and AISB's innovative platform, patients and healthcare professionals will benefit from advanced diagnostics and personalized care. |
| | · | MRNA Scientific和BGLC认为，这项战略投资将通过整合到AISB的AICM和AiCare应用程序，使BGLC的血液基因组筛查（BGS）液体活检和其他诊断服务能够更好地推向市场，让更多的客户和医疗保健提供者获得这些服务，从而实现通过医疗保健提供者和患者直接预订。 |
| | · | 通过将MRNA在基因组学方面的专业知识与AISB的创新平台相结合，患者和医疗保健专业人员将受益于先进的诊断和个性化护理。 |
Digital Health & AI Market:
| | · | The global digital health market size was estimated at USD 240.9 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 21.9% from 2024 to 20301. |
| | · | The global market size for AI in Healthcare is expected to reach USD 187.7 billion by 2030 with a compound annual growth rate (CAGR) of 38.5% from 2024 to 20302. |
| | · | Given the market size and opportunities in Digital Health and AI in Healthcare, MRNA and BGLC will closely consider opportunities to increase our participation in this market, including the potential to increase our investment in AISB and other technology platforms. |
| | · | 据估计，2023年全球数字医疗市场规模为2409亿美元，预计从2024年到20301年将以21.9％的复合年增长率（CAGR）增长。 |
| | · | 到2030年，医疗领域人工智能的全球市场规模预计将达到1877亿美元，从2024年到20302年，复合年增长率（CAGR）为38.5％。 |
| | · | 鉴于数字健康和医疗保健人工智能的市场规模和机遇，MRNA和BGLC将仔细考虑增加我们在该市场的参与的机会，包括增加对AISB和其他技术平台投资的可能性。 |
| | · |
Projected Revenue in Malaysia: |
| | | o | As stated in its investment documents, AISB anticipates substantial revenue growth driven by increased adoption of aiCMS, with projections reaching RM 75million collectively for 2024-2028. |
| | | o | The platform's comprehensive suite of services positions it as a game-changer in the Malaysian healthcare landscape. |
| | | o | These revenue projections were part of the approved prospectus on the Securities Commission of Malaysia approved pitchIN Funding platform. |
| | | o | 正如其投资文件中所述，AISB预计，由于AICM的采用率的提高，收入将大幅增长，预计2024-2028年总收入将达到7500万令吉。 |
| | | o | 该平台的全方位服务使其成为马来西亚医疗保健领域的游戏规则改变者。 |
| | | o | 这些收入预测是马来西亚证券委员会批准的Pitchin Funding平台批准的招股说明书的一部分。 |
| | · |
Clinics and Service Providers: |
| | | o | AISB aims to onboard a significant number of healthcare and wellness providers, and corporations. |
| | | o | Since its recent launch, aiCMS has already proven market traction with over 30 healthcare providers and corporations in its initial segue into this broad market. |
| | | o | AISB的目标是招募大量的医疗保健和保健提供商和公司。 |
| | | o | 自最近推出以来，AICMS已经证明了市场吸引力，最初有30多家医疗保健提供商和公司进入这个广阔的市场。 |
| | · |
User Base and Health Records: |
| | | o | With 145,000+ registered users and 340,000+ individual health records in its database, the aiCMS platform is already making an impact in the market. |
| | | o | The platform's scalability has the potential for exponential growth. |
| | | o | AICMS平台拥有超过14.5万名注册用户，其数据库中有340,000多条个人健康记录，已经在市场上产生了影响。 |
| | | o | 该平台的可扩展性有可能实现指数级增长。 |
| | · |
Mr. Sam Tan, CEO, BioNexus Gene Lab Corporation: "Our investment in AISB reflects our belief in their transformative healthcare solutions. Together, we aim to revolutionize patient care through predictive and generative AI." |
| | | |
| | · |
Mr. Andrew Teng, CEO, Ascension Innovation Sdn Bhd: "We welcome MRNA Scientific's support and look forward to leveraging their expertise. The future of healthcare lies in predictive analytics and personalized solutions." |
| | · |
陈山先生，BioneXUS 基因实验室公司首席执行官：“我们对AISB的投资反映了我们对他们的变革性医疗解决方案的信念。我们的共同目标是通过预测性和生成式人工智能彻底改变患者护理。” |
| | | |
| | · |
腾升创新私人有限公司首席执行官安德鲁·滕先生: “我们欢迎MRNA Scientific的支持，并期待利用他们的专业知识。医疗保健的未来在于预测分析和个性化解决方案。” |
The handover ceremony took place at the Apollo Men's Wellness Centre in Starhill, Kuala Lumpur on April 18th, 2024, witnessed by Mr. Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp (BGLC).
移交仪式于2024年4月18日在吉隆坡Starhill的阿波罗男士健康中心举行，Bionexus基因实验室公司（BGLC）首席执行官山姆·陈先生见证。
